Claims for Patent: 5,168,062

✉ Email this page to a colleague

Summary for Patent: 5,168,062

Title:	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
Abstract:	The cloning of a eucaryotic promoter-regulatory region that functions preferentially in human cells is disclosed. The invention is exemplified by the cloning of a section of the human cytomegalovirus genome comprising a DNA sequence with regulatory and promoter signals and an initiation site for RNA synthesis. The fragment, termed the human cytomegalovirus (HCMV) promoter-regulatory sequence, was obtained from purified HCMV DNA.
Inventor(s):	Stinski; Mark F. (Iowa City, IA)
Assignee:	University of Iowa Research Foundation (Oakdale, IA)
Application Number:	07/582,130
Patent Claims:	1. A recombinant DNA plasmid comprising DNA sequence isolated from the immediate-early, promoter-regulatory region of human cytomegalovirus and a heterologous gene positioned downstream and operatively linked to said sequence. 2. A recombinant DNA plasmid containing a DNA sequence consisting essentially of: ##STR1## and a heterologous gene positioned downstream and operatively linked to said sequence. 3. An isolated DNA sequence consisting essentially of the immediate-early, promoter-regulatory region of human cytomegalovirus, wherein said sequence comprises repeat sequences of 19, 28, 16 and 21 base pairs in length. 4. A eucaryotic host cell transformed with a recombinant DNA plasmid comprising a DNA sequence isolated from the immediate-early, promoter-regulatory region of human cytomegalovirus and a heterologous gene positioned downstream and operatively linked to said sequence. 5. The transformed eucaryotic host cell of claim 4 wherein said host cell is a mammalian host cell. 6. A plasmid pIEPR12. 7. A microorganism transformed with the plasmid pIEPR12. 8. E. coli RecBC.sup.- pIEPR12.

Details for Patent 5,168,062

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	November 23, 2004	5,168,062	2009-12-01
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 5,168,062

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
United States of America	5385839	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.